Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 5/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15889026 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL10147394 | 0.78 | KDM4E (0.40) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL16383865 | 0.78 | MAPT (0.40) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL12437141 | 0.76 | TYMS (0.39) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL13183571 | 0.70 | GAA (0.45) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL6905898 | 0.69 | ALDH1A1 (0.47) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL12437143 | 0.69 | PARP10 (0.36) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL10141066 | 0.69 | PARP10 (0.36) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL10141068 | 0.65 | RAB9A (0.33) | KDM4EALDH1A1POLBGAAMAPT | |
| SCHEMBL22487889 | 0.65 | HRH4 (0.35) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189129-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, NSUN2 | KDM4E 1321/4885ALDH1A1 901/4885POLB 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.